Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gellic (formerly marketed as Gleitgelen) is a topical vaginal gel developed and manufactured by the Austrian pharmaceutical company Pharmazeutische Fabrik Montavit. It is primarily indicated for the management of vaginal dryness and associated symptoms such as itching, burning, and pain. The product is a water-based, hormone-free lubricant that contains chlorhexidine dihydrochloride (0.1 mg per 1 g of gel) as an active antiseptic ingredient. Gellic functions mechanically to increase the lubricity of the vaginal mucous membrane and acts as a moisturizer, while the inclusion of chlorhexidine provides local antibacterial protection. It is compatible with latex condoms and is free from fats, parabens, and hormones. Although it contains a pharmaceutical active, it is classified as a medical device in various markets due to its primary mechanical mode of action.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Gellic.